Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03399448 · ClinicalTrials.gov registry record · Phase 1
NY-ESO-1-redirected CRISPR (TCRendo and PD1) Edited T Cells (NYCE T Cells)
A Phase 1 study, sponsored by University of Pennsylvania.
- Terminated
- Registry status
- Phase 1
- Development phase
- 3
- Enrollment target
NCT03399448: Clinical Trial Phase 1 study, sponsored by University of Pennsylvania.
NCT03399448 is a Phase 1 study that was terminated before completion, run by University of Pennsylvania. The registered enrollment target is 3 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03399448, a Phase 1 study, was terminated before completion, sponsored by University of Pennsylvania.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 3 participants
- Enrollment target
Study Summary
This is a first-in-human trial proposed to test HLA-A\*0201 restricted NY-ESO-1 redirected T cells with edited endogenous T cell receptor and PD-1.
Interventions
- DRUG Cyclophosphamide
- DRUG Fludarabine
- BIOLOGICAL NY-ESO-1 redirected autologous T cells with CRISPR edited endogenous TCR and PD-1
- DEVICE NY-ESO-1 expression testing
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2018-09-05 |
| Est. Completion | 2020-10-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03399448
The ClinicalTrials.gov registry entry for NCT03399448 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 3 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Pennsylvania, which has 1,423 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Cyclophosphamide is the first listed.
NCT03399448 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03399448 about?
NCT03399448 is a clinical study titled "NY-ESO-1-redirected CRISPR (TCRendo and PD1) Edited T Cells (NYCE T Cells)". This is a first-in-human trial proposed to test HLA-A\*0201 restricted NY-ESO-1 redirected T cells with edited endogenous T cell receptor and PD-1.
What is the current status of trial NCT03399448?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 3 participants. The study started on 2018-09-05. Estimated completion is 2020-10-09.
What interventions are being tested in trial NCT03399448?
The interventions under investigation include: Cyclophosphamide (DRUG), Fludarabine (DRUG), NY-ESO-1 redirected autologous T cells with CRISPR edited endogenous TCR and PD-1 (BIOLOGICAL), NY-ESO-1 expression testing (DEVICE).
Who is sponsoring clinical trial NCT03399448?
This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.